Hirose Kohei, Yajima Shugo, Ogasawara Ryo Andy, Imasato Naoki, Katsumura Sao, Kataoka Madoka, Nakanishi Yasukazu, Masuda Hitoshi
National Cancer Center Hospital East, Chiba, Japan.
J Frailty Sarcopenia Falls. 2024 Sep 1;9(3):201-206. doi: 10.22540/JFSF-09-201. eCollection 2024 Sep.
We aimed to evaluate the association between scores on each item of the SARC-F questionnaire and life expectancy in patients undergoing major surgery for urologic cancer.
This retrospective study included 1018 patients undergoing elective major urologic cancer surgery. All patients completed the SARC-F questionnaire preoperatively. Demographic and clinical data were collected. The primary endpoint was an association between SARC-F scores and overall survival (OS).
Of the 1018 patients, the median age was 72 years and 920 (90%) were male. Multivariate analysis revealed four factors significantly and independently associated with shorter OS: assistance with walking score ≥1 (Hazard ratio: HR=2.18, =0.044), cancer stages ≥ III (HR=7.98, <0.001), high blood loss ≥78 ml or blood transfusion during surgery (HR=4.53, =0.007 and HR=2.41, =0.037, respectively).
This study found that among the items of the SARC-F questionnaire, assistance with walking was a strong predictor of life expectancy. Incorporating such a simple screening tool into the preoperative assessment would help to ensure more appropriate perioperative care for urologic cancer patients.
我们旨在评估接受泌尿外科癌症大手术患者的SARC - F问卷各项目得分与预期寿命之间的关联。
这项回顾性研究纳入了1018例接受择期泌尿外科癌症大手术的患者。所有患者术前均完成了SARC - F问卷。收集了人口统计学和临床数据。主要终点是SARC - F得分与总生存期（OS）之间的关联。
1018例患者中，中位年龄为 72岁，920例（90%）为男性。多因素分析显示，有四个因素与较短的总生存期显著且独立相关：行走辅助得分≥1（风险比：HR = 2.18，P = 0.044）、癌症分期≥III期（HR = 7.98，P < 0.001）、术中失血≥78 ml或输血（分别为HR = 4.53，P = 0.007和HR = 2.41，P = 0.037）。
本研究发现，在SARC - F问卷项目中，行走辅助是预期寿命的有力预测指标。将这样一个简单的筛查工具纳入术前评估将有助于确保为泌尿外科癌症患者提供更合适的围手术期护理。
